Blinding, shorter duration help reduce placebo responses in systemic therapy trials in AD
In clinical trials of systemic therapy in atopic dermatitis (AD), the integration of double- and triple-blinding can lower placebo responses, according to the results of a systematic review and meta-analysis. Other means of achieving this include balancing of patient sex distribution, disallowing concomitant use of prescription topical therapy and having shorter study durations.
Blinding, shorter duration help reduce placebo responses in systemic therapy trials in AD
17 Dec 2019